Abstract
Proxazole or 3-α-phenylpropyl-5-β-diethylaminoethyl-1, 2, 4-oxadiazole citrate, is an unusual drug because it possesses both anti-inflammatory and antispasmodic properties (1) and because each of these two properties has some uncommon features. The antiinflammatory action takes place mostly against edematous responses and is devoid of ulcerogenic effects which are instead produced by most anti-inflammatory drugs; moreover proxazole prevents indomethacin-induced ulcers without exerting any anti-secretory effect (2-3). The antispasmodic activity results in a specific inhibition of smooth muscle spasm, both at the vascular and at the intestinal level, without significant interferences with the physiologic activity of that tissue (1-4).
The above data suggested a potential interest in the use of proxazole in pathological situations sustained by ischemic-inflammatory processes. Therefore experiments were undertaken to test proxazole in rats operated according to Grollman (6). In such animals the induced hypertension may be measured and used as an index of renal alterations.
